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Mutation spectrum of NOD2
reveals recessive inheritance
as a main driver of Early Onset
Crohn’s Disease
Julie E. Horowitz1, Neil Warner2,3, Jeffrey Staples1, Eileen Crowley2,3,4, Nehal Gosalia1,
Ryan Murchie2,3, Cristopher Van Hout1, Karoline Fiedler2,3, Gabriel Welch1,
Alejandra Klauer King1, Jeffrey G. Reid1, John D. Overton1, Aris Baras1, Alan R. Shuldiner1,
Anne Griffiths2, Omri Gottesman1, Aleixo M. Muise2,3,5* & Claudia Gonzaga‑Jauregui1*
Inflammatory bowel disease (IBD), clinically defined as Crohn’s disease (CD), ulcerative colitis (UC), or
IBD-unclassified, results in chronic inflammation of the gastrointestinal tract in genetically susceptible
hosts. Pediatric onset IBD represents ≥ 25% of all IBD diagnoses and often presents with intestinal
stricturing, perianal disease, and failed response to conventional treatments. NOD2 was the first and
is the most replicated locus associated with adult IBD, to date. However, its role in pediatric onset
IBD is not well understood. We performed whole-exome sequencing on a cohort of 1,183 patients
with pediatric onset IBD (ages 0–18.5 years). We identified 92 probands with biallelic rare and low
frequency NOD2 variants accounting for approximately 8% of our cohort, suggesting a Mendelian
inheritance pattern of disease. Additionally, we investigated the contribution of recessive inheritance
of NOD2 alleles in adult IBD patients from a large clinical population cohort. We found that recessive
inheritance of NOD2 variants explains ~ 7% of cases in this adult IBD cohort, including ~ 10% of CD
cases, confirming the observations from our pediatric IBD cohort. Exploration of EHR data showed
that several of these adult IBD patients obtained their initial IBD diagnosis before 18 years of age,
consistent with early onset disease. While it has been previously reported that carriers of more
than one NOD2 risk alleles have increased susceptibility to Crohn’s Disease (CD), our data formally
demonstrate that recessive inheritance of NOD2 alleles is a mechanistic driver of early onset IBD,
specifically CD, likely due to loss of NOD2 protein function. Collectively, our findings show that
recessive inheritance of rare and low frequency deleterious NOD2 variants account for 7–10% of CD
cases and implicate NOD2 as a Mendelian disease gene for early onset Crohn’s Disease.
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal (GI) tract that
arises as part of an inappropriate response to commensal or pathogenic microbiota in a genetically susceptible
individual1–4. IBD encompasses Crohn’s Disease (CD); ulcerative colitis (UC); and IBD unclassified (IBDU).
The etiology of IBD is complex and has been attributed to defects in a number of cellular pathways including
pathogen sensing, autophagy, maintenance of immune homeostasis, and intestinal barrier function, among
other processes3–18.
Great effort has been invested into defining the genetic factors that confer IBD susceptibility. To date, > 200
unique loci have been associated with IBD through genome-wide association studies (GWAS), primarily in adult
populations19,20. Nearly all the identified susceptibility loci exhibit low effect sizes (ORs ~ 1.0–1.5) i ndividually19,
and collectively account for less than 20% of the heritable risk for IBD19–21. These observations support a complex
disease model in which common variants of modest effect sizes interact with environmental factors including
diet, smoking, and the intestinal microbiome22,23 to give rise to IBD susceptibility.
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The earliest and most replicated genetic associations with IBD24–26 correspond to a locus on chromosome
16 that encompasses the nucleotide-binding and oligomerization domain-containing 2 (NOD2) gene, with an
average allelic odds ratio across multiple studies of 3.119,20. NOD2 encodes an intracellular microbial sensor that
recognizes muramyl dipeptide (MDP) motifs found on bacterial p
 eptidoglycans27,28. Upon activation, NOD2
29
protein signals through the NF-κB family of proteins to modulate transcription of genes encoding pro-inflammatory cytokines IL-8, TNF-α, and IL-1β30–32, among others. Variation in NOD2 accounts for approximately
20% of the genetic risk among CD cases, with three variants—p.R702W (ExAC MAF = 0.0227 across all populations), p.G908R (ExAC MAF = 0.0099), and p.L1007fs (ExAC MAF = 0.0131)—accounting for over 80% of the
disease-causing mutations in NOD2 associated with adult CD33, albeit not with UC; and particularly ileal versus
colonic CD34. These three “common” risk variants, typically observed in a heterozygous state, are predicted to be
loss-of-function alleles that impair NF-κB activation in response to MDP ligands, in vitro28,35–37.
With the assumption that genetic risk has a disproportionate effect over environmental risk in early onset
disease, recent studies have focused on pediatric IBD cases (diagnosed < 18y)38–40. Pediatric IBD patients comprise
20–25% of all IBD cases and are typically more clinically severe than adult-onset patients, often exhibiting disease
of the upper GI tract, small bowel inflammation, and perianal disease as well as failure to thrive and poor clinical
response4,40. Results from GWAS conducted in this group of severely affected patients indicate that associated
loci in early onset IBD significantly overlap with adult IBD loci, including both the NOD2 locus and an additional 28 CD-specific loci previously implicated in adult-onset I BD41–43. As the mechanism for these “common”
IBD susceptibility loci in the pathogenesis of early onset IBD remains u
 nclear44, we performed whole-exome
sequencing and rare variant analysis on a cohort of 1,183 pediatric onset IBD patients to elucidate the role of
rare protein coding variation in IBD-associated genes, specifically NOD2, in this disease.

Subjects and methods

Samples. We obtained informed consent for all individuals included in this study or parental informed
consent was obtained for minors under 18 years of age. For pediatric IBD, we studied a cohort of 1,183 probands
with pediatric onset IBD (ages 0–18.5 years), including their affected and unaffected parents and siblings, where
available (total samples = 2,704). Individuals were consented for genetic studies under an IRB-approved protocol
by the Toronto Hospital for Sick Children, Canada as part of the NEOPICS initiative (https://www.neopics.org/).
DiscovEHR participants are a subset of the Geisinger MyCode Community Health Initiative. The MyCode
Community Health Initiative is a repository of blood, serum, and DNA samples from Geisinger patients that
have been consented to participate in research and donate samples for broad research use, including genomic
analyses that can be linked to de-identified electronic health record (EHR) information. DiscovEHR participants
were consented in accordance with the Geisinger Institutional Review Board approved protocol, Study number
2006–0258.
Helsinki guidelines. All human experiments followed relevant guidelines and regulations according to the

Declaration of Helsinki.

Exome sequencing. Sample preparation, whole exome sequencing, and sequence data production for both
the pediatric IBD cohort and the DiscovEHR cohort were performed at the Regeneron Genetics Center (RGC)
as previously described45. In brief, 1ug of high-quality genomic DNA was used for exome capture utilizing the
NimbleGen VCRome 2.1 design. Captured libraries were sequenced on the Illumina HiSeq 2500 platform with
v4 chemistry using paired-end 75 bp reads. Exome sequencing was performed such that > 85% of the bases were
covered at 20 × or greater. Raw sequence reads were mapped and aligned to the GRCh37/hg19 human genome
reference assembly, and called variants were annotated and analyzed using an RGC implemented cloud-based
pipeline. Briefly, variants were filtered based on their observed minor allele frequencies at a < 2% cutoff using the
internal RGC database and other public population control databases to filter out common polymorphisms and
high frequency, likely benign variants in consideration of disease prevalence.
DiscovEHR statistical analyses.

For NOD2 locus-specific statistical analyses in the DiscovEHR cohort,
individuals with ICD diagnoses in their EHR consistent with IBD and carriers of NOD2 variants were annotated
and filtered using the same pipeline as for the pediatric IBD cases. Odds ratios for all genetic models (additive,
recessive and genotypic) were calculated using Fisher’s exact test with no covariates.
For large-scale association analyses, variants were annotated with snpEff using Ensembl 85 gene d
 efinitions46.
Gene definitions were restricted to transcripts with annotated start and stop codons, totaling 19,467 proteincoding genes. Predicted loss-of-function (pLoF) variants were defined as any of the following: variants leading
to a premature stop codon, loss of a start codon, or loss of a stop codon; single-nucleotide variants or indels
disrupting canonical splice donor or acceptor sites; and frame-shifting indels predicted to result in premature stop
codons. Phasing of putative compound heterozygotes was performed as previously described for this c ohort47
using a combination of familial relationship based p
 hasing48 and population allele frequency based phasing with
49
EAGLE . Biallelic pLoF and predicted deleterious missense variants with a MAF < 5% in the discovery set of
58,138 European ancestry individuals were aggregated at a gene level. Variants were aggregated for gene burden
tests in two ways as previously described45,50: pLoFs only and pLoFs plus missense variants (M3) predicted to be
deleterious (pdNS) by five different bioinformatic prediction algorithms for functional effects, namely S IFT51,
LRT52, MutationTaster53, PolyPhen2 HumDiv, and PolyPhen2 HumVar54. Genotypes were coded as follows:
homozygous reference as 0, heterozygotes as 1, and homozygous alternative or compound heterozygous as 2.
PLINK 1.955 was used to run Firth logistic regression under both additive and recessive models using the ICD10
K50 phenotype, which is the ICD10 diagnosis code for Crohn’s disease [regional enteritis], ( Ncases = 613 versus
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Tissue involvement
NOD2 variant

# EO-IBD probands

Mean age (range)

% CD Dx

Colon (%)

Ileum (%)

Perianal (%)

Compound heterozygous
Rare/rare

4 T; 1S

12.5 (9.0–14.6)

88.9

80.0

60.0

40.0

Common/rare

1Q; 9 T; 6D; 14S

12.6 (5.5–16.5)

93.1

57.1

82.1

25.0

Common/common

17 T; 5D; 10S

11.8 (2.1–18.5)

90.6

56.3

90.6

25.0

Homozygous
Rare

1D; 2S

p.R702W

1Q; 2 T; 3D; 1S

9.6 (4.2–15.1)

66.7

33.3

33.3

33.3

11.7 (5.8–13.8)

100

85.7

57.1

42.9

p.G908R

2 T; 1D; 2S

10.6 (7.7–13.7

80.0

40.0

40.0

0.0

p.L1007fs

4 T; 2D; 4S

12.1 (5.9–13.4)

100

60.0

90.0

20.0

Table 1.  Mutation spectrum of recessive NOD2 variants in an EO-IBD cohort. Common NOD2 variants
refer to the three main low-frequency Crohn’s Disease risk variants p.R702W, p.G908R, and p.L1007fs; Rare
NOD2 variants refer to other low-frequency variants (MAF ≤ 5%). Q, quartet; T, trio; D, duo; S, singleton; Dx,
diagnosis.

Ncontrols = 54,802). Phenome-wide associations were performed using all ICD-10 disease diagnosis codes available for the DiscovEHR dataset.

Results

An initial analysis of the exome sequencing data for pathogenic and expected pathogenic variants in genes known
to cause monogenic forms of IBD in all probands from our pediatric IBD cohort identified 40 rare variants in
31 probands56. Additionally, we performed trio-based analysis of 492 complete trios using a proband-based
analytical pipeline to identify all recessive (compound heterozygous and homozygous), X-linked, and de novo
variants of interest in the affected probands. In our initial analyses, we identified 10 families with recessive
(compound heterozygous or homozygous), rare variants (2% ≤ MAF) in NOD2, all with a diagnosis of CD. We
observed that some of the rare variants in these probands were inherited in trans from previously-reported CD
risk alleles, mainly the p.G908R missense variant. We identified two individuals who are compound heterozygous for the p.G908R risk allele in trans with a less common NOD2 CD risk variant (p.N852S) in one case and
a novel truncating indel (p.S506Vfs*73) in the second case (Supplementary Table 1, Fam008 and Fam009). The
observation of a CD-associated NOD2 risk allele in trans from other rare or novel alleles led us to survey the
rest of the probands, including singletons and those part of incomplete trios, for recessive inheritance, either in
a homozygous or compound heterozygous manner, of NOD2 variants, but expanding our allelic range to lowfrequency variants (2% ≤ MAF ≤ 5%). Through this approach we identified 108 probands with putative recessive
NOD2 variants. Visual inspection of sequence reads and orthogonal confirmation through Sanger sequencing
excluded 13 probands with variants inherited in cis from an unaffected parent or heterozygous variants that were
initially called as homozygous due to low coverage of the region and skewed allelic balance. Of note, we identified
5 probands carrying p.L1007fs and p.M863V risk variants, 4 of which were confirmed to occur in cis and were
inherited from an unaffected parent. The remaining case with p.L1007fs and p.M863V was a singleton and thus
phase could not be determined. These two variants segregate in cis within the same haplotype, as confirmed by
segregation within the trios and as previously o
 bserved57. Therefore, we excluded these 4 probands from our
final count of recessively-inherited NOD2 variants. Similarly, we identified 3 probands from 3 complete trios
segregating the p.S431L and p.V793M reported risk variants in cis inherited from an unaffected carrier parent;
these probands were also excluded. Three additional probands were excluded on the basis of a re-evaluation of
the phenotype that excluded a clinical diagnosis of IBD.
Thus, we identified 92 probands with confirmed recessive NOD2 variants within our pediatric onset IBD
cohort, none of which had variants of interest in known monogenic IBD associated genes. These included: 25
probands carrying homozygous variants, 41 probands with confirmed compound heterozygous variants, and
an additional 26 singleton probands with putative compound heterozygous variants where phasing could not be
performed (Supplementary Table 1, Supplementary Fig. 1). The majority of the compound heterozygous individuals (65/67) carry a known NOD2 CD-risk allele in addition to either another known NOD2 CD-risk allele or a
novel NOD2 variant, including some truncating loss-of-function variants supporting loss or impaired function
of NOD2 in the pathophysiology of C
 D6. In total, 92 of 1,183 (7.8%) of the probands in our pediatric onset IBD
cohort conformed to a recessive, Mendelian inheritance mode for NOD2 rare and low frequency (MAF ≤ 5%)
deleterious variants (Table 1, Fig. 1, Supplementary Table 1, and Supplementary Table 4).
The 92 pediatric patients homozygous for NOD2 mutations were predominantly male (71%) with a median
age at diagnosis of 12.5 years (Supplementary Table 1). At diagnosis, 83% displayed diagnostic features of Crohn’s
disease. 23% of the cohort displayed a constellation of extra-intestinal manifestations, mainly large joint arthritis,
chronic recurrent multifocal osteomyelitis, recurrent fevers, erythema nodosum, and pyoderma gangrenosum.
Only 6% of the cohort showed significant perianal disease (namely fistulae and abscesses; skin tags and fissures
were not considered as perianal disease) (Supplementary Table 1). Per the Montreal classification of IBD58, 44%
of the overall cohort of patients presented with ileal disease at diagnosis (L1). 25% presented with ileocolonic
disease (L3) and 10% displayed features of colonic inflammation only (L2). Isolated upper disease was only
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Figure 1.  Mutation spectrum of NOD2 in inflammatory bowel disease (IBD) patients. NOD2 variation
identified in patients with pediatric early onset IBD (upper) and adult IBD cohort from the RGC-GHS
DiscovEHR collaboration (lower). Variants in blue were observed in both cohorts; variants in red are predicted
loss-of-function that result in nonsense mediated decay. The three “common” low-frequency Crohn’s Disease
risk variants are highlighted: R702W (purple), G908R (brown), and L1007fs (green). Also depicted are the
NOD2 protein structural domains: two caspase activation and recruitment domains (CARD), a nucleotide
binding and oligomerization (NOD) domain, and leucine rich repeat domains in yellow.

NOD2 variants

# IBD patients

Mean age (range)

# CD Dx

% CD Dx

# Male

% Male

# Perianal

% Perianal

Homozygous
p.R702W

10

47.3 (16.0–76.3)

10

100

5

50.0

1

10.0

p.G908R

0

–

–

–

–

–

–

–

p.L1007fs

8

40.25 (11.0–75.0)

8

100

4

50.0

3

37.5

Compound heterozygous
Common/common
p.R702W/p.G908R

6

48.5 (11.4–54.2)

3

50.0

5

83.3

1

16.7

p.R702W/p.L1007fs

11

38.5 (21.5–69.2)

8

72.7

3

27.3

2

18.2

p.G908R/p.L1007fs
Common/rare
Rare/rare

5

35.2 (20.0–52.4)

4

80.0

2

40.0

0

0.0

16

40.3 (10.8–66.1)

8

50.0

8

50.0

6

37.5

8

60.9 (30.8–78.7)

4

50.0

3

37.5

1

12.5

Table 2.  Mutation spectrum of recessive NOD2 variants in the RGC-GHS DiscovEHR adult IBD cohort.
Common NOD2 variants refer to the three main low-frequency Crohn’s Disease risk variants p.R702W,
p.G908R, and p.L1007fs; Rare NOD2 variants refer to other low-frequency variants (MAF ≤ 5%). Dx, diagnosis.

present in 2% of the cohort (L4). We observed a progression of ileal disease in 21% (18.5% stricturing; 2.5%
penetrating) with 21% requiring a resection. On review of the Crohn’s disease patients only, 50% displayed L1
disease (terminal ileal +/− limited cecal disease), 32.9% L3 (ileocolonic) disease; 86.8% B1 (non-stricturing, nonpenetrating) disease, 10.5% B2 (stricturing) disease. Of the 92 patients with biallelic variants in NOD2, 42.4%
(n = 39) had ileal disease, 27.17% (n = 25) had ileocolonic disease, and 11.95% (n = 11) had colonic inflammation
only (Supplementary Table 1).
Given the substantial contribution of recessive NOD2 variants to CD in our pediatric onset IBD cohort and
the known contribution of NOD2 to adult CD, we next investigated the contribution of NOD2 recessivity in a
large clinical population. For this, we examined a cohort of adult IBD patients from the Geisinger-Regeneron
DiscovEHR collaboration45. A key feature of the DiscovEHR study is the ability to link genomic sequence data
to de-identified electronic health records (EHRs). Within this cohort, we identified 984 patients (of 51,289 total
sequenced DiscovEHR patient-participants) with a diagnosis of IBD, defined as having a problem list entry or
an encounter diagnosis entered for two separate clinical encounters on separate calendar days for the ICD-9
codes 555* (Regional enteritis) or 556* (Ulcerative enterocolitis) or ICD-10 K50* (Crohn’s disease [regional
enteritis]) or K51* (Ulcerative colitis). For our analysis, we surveyed all instances of homozygous NOD2 rare
and low frequency variants (MAF ≤ 5%); the same parameters applied to our pediatric IBD probands. Among
patients with an IBD diagnosis, we identified 18 individuals who are either homozygous for the p.R702W risk
allele (N = 10) or homozygous for the p.L1007fs allele (N = 8) (Table 2, Supplementary Fig. 2). We did not identify
any p.G908R homozygous individuals with an IBD diagnosis in this cohort. Next, we looked for instances of putative compound heterozygosity among these adult IBD DiscovEHR patients. First, we searched for occurrences
of two or more of the three most prevalent NOD2 risk alleles (p.R702W, p.G908R, or p.L1007fs) in these individuals. We identified putative compound heterozygosity for the three main CD risk alleles, p.R702W/p.G908R
(N = 6), p.G908R/p.L1007fs (N = 5), and p.R702W/p.L1007fs (N = 11) (Table 2). We also observed instances of
putative compound heterozygosity for each of the three main CD risk alleles along with either a rarer CD risk
allele or a novel allele or two rare alleles in trans (N = 24), parallel to the findings in our pediatric IBD cohort.
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Figure 2.  Phenome wide association analysis (PheWAS) of ICD diagnostic codes with biallelic recessive
genotypes of NOD2. Analysis shows that NOD2 recessive status significantly associates with Crohn’s disease and
related diagnoses.
Using familial relationships and pedigree r econstruction47, we were able to confirm appropriate segregation for
32 of the 64 DiscovEHR recessive NOD2 variant carriers with IBD, including trans inheritance in 13 putative
compound heterozygotes (Supplementary Fig. 2). The other 32 were singleton cases where phase could not be
confirmed. Overall, we identified 64 homozygous or putative compound heterozygous NOD2 variant carriers
in the DiscovEHR IBD cohort, accounting for 6.5% of patients with an IBD diagnosis in this clinical population
(Fig. 1, Supplementary Table 4).
We were also able to evaluate longitudinal de-identified medical records for all patients within the DiscovEHR
IBD cohort. According to their EHR data, 21 patients received diagnoses of both UC and CD. To clarify these
diagnoses, we performed manual evaluation of EHR information (which includes demographics, encounter
and problem list diagnosis codes, procedure codes, and medications) for all 64 homozygous or compound
heterozygous NOD2 patients with an IBD diagnosis. Through this review, 6 homozygotes exhibited a conflicting diagnosis of CD, of which 5 were resolved as CD and 1 could not be defined; 16 compound heterozygotes
exhibited a conflicting diagnosis of CD of which 6 were resolved as CD and 10 were resolved as UC (Supplementary Table 3). In total, we found that 17/18 (94.4%) of homozygous NOD2 individuals and 33/46 (71.7%)
compound heterozygous had a diagnosis of CD and that 9.9% of all CD cases in this cohort could be attributed
to homozygous or compound heterozygous variants in NOD2. We next investigated age of disease onset using
the first recorded date of an IBD diagnosis in the EHR. We identified 6 carriers of recessive NOD2 variants (9.4%
of our recessive NOD2 patients with IBD) who were diagnosed with IBD prior to 18 years of age. We also identified additional 11 carriers of recessive NOD2 variants diagnosed with IBD prior to age 30 years, which is at or
below the average age of IBD diagnosis59 and is consistent with earlier disease onset (Supplementary Table 3). Of
note, our DiscovEHR cohort data extends to a median of 14 years (and maximum of 25 years) of electronically
recorded medical information, concurrent with the adoption of the EHR by the Geisinger Health System. Since
72.4% of our cohort is currently over the age of 50 years, we cannot determine whether the age of onset for IBD
occurred prior to the first electronically recorded date of an IBD diagnosis for many recessive NOD2 patients;
thus it is possible that other individuals with homozygous or compound heterozygous variants in NOD2 might
have had pediatric-onset disease that was not captured in the EHR.
Incidentally, our manual evaluation of the EHR data for these individuals also revealed that 75% of the IBD
patients had a diagnosis record of anemia in their history. In about 58% of these cases the anemia diagnosis was
given concurrent or before the first recorded diagnosis of IBD, with an average of 2.26 years prior. This observation is consistent with previous reports of anemia as an important yet underappreciated and undertreated
comorbidity in I BD60,61, but also suggests that anemia may be an early indicator of IBD onset. Interestingly, 16
of 48 individuals homozygous for the p.L1007fs variant that do not have a diagnosis of IBD and for which we
were able to review their EHR information had a diagnosis of anemia in their chart and 11 of them had diagnosis codes related to gastrointestinal complaints. To further assess whether NOD2 genotype status associated
with other phenotypes, we performed a PheWAS analysis using all ICD codes recorded in the EHR of NOD2
homozygous and compound heterozygous individuals. This analysis showed that NOD2 recessivity significantly
and specifically associates with Crohn’s disease (Fig. 2).
Next, given the recessive inheritance of NOD2 variants observed in both our pediatric onset and adult
IBD cohorts, we estimated the disease risk for the three main known CD risk alleles (p.R702W, p.G908R, and
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DiscovEHR
controls
(N = 50,305)

DiscovEHR
IBD cases
(N = 984)

Additive model
OR [95% CI]
(P-value)

Genotypic
model
(heterozygous)
OR [95% CI]
(P-value)

Genotypic
model
(homozygous)
OR [95% CI]
(P-value)

Recessive
model OR [95%
CI] (P-value)
ExAC MAF

IBD exomes
OR (P-value)

NOD2 variant

DiscovEHR
MAF

p.R702W

0.050

Het = 4727;
Hom = 145

Het = 116;
Hom = 11

1.43 [1.20–1.71]
(4.63 × 10–5)

1.30 [1.06–1.58]
(0.008765)

4.02 [2.17–7.45]
(6.86 × 10–6)

3.91 [2.11–7.24]
(2.86 × 10–6)

0.035

1.92 (< 1 × 10–16)

p.G908R

0.017

Het = 1683;
Hom = 16

Het = 52;
Hom = 0

1.56 [1.18–2.06]
(0.001544)

1.61 [1.21–2.13]
(0.00087)

NA

NA

0.012

1.91 (< 1 × 10–16)

p.L1007fs

0.029

Het = 2808;
Hom = 42

Het = 86;
Hom = 8

1.84 [1.50–2.26]
(1.69 × 10–9)

1.63 [1.30–2.04]
(1.67 × 10–5)

10.15
[4.75–21.69]
(1.38 × 10–12)

9.80
[4.59–20.94]
(3.80 × 10–13)

0.018

2.57 (< 1 × 10–16)

Compound Het

N = 263

N = 22

Composite
NOD2

Het = 8955;
Rec = 450

Het = 232;
Rec = 41

4.35 [2.80–6.75]
(8.14 × 10–13)
1.64 [1.45–1.86]
(4.58 × 10–15)
3.29 [2.56–4.23]
(2 alleles
predicted)

1.49 [1.28–1.73]
(2.75 × 10–7)

5.24 [3.77–7.27]
(4.31 × 10–22)

4.81 [3.47–6.67]
(1.63 × 10–25)

Table 3.  OR calculations for 3 NOD2 CD risk alleles (p.R702W, p.G908R, p.L1007fs), composite, and
compound heterozygous combinations in the DiscovEHR cohort. There were no homozygotes for the p.G908R
variant affected with IBD in our cohort; therefore, no genotypic homozygous and recessive ORs could be
calculated. The ‘Composite NOD2′ calculations account for all alleles and genotypes for the 3 CD risk variants
in the different genetic models.

Figure 3.  Graphical representation of Odds Ratio (OR) point estimates and 95% confidence intervals (CI) for
the three main CD risk alleles (p.R702W, p.G908R, p.L1007fs) under additive, genotypic, and recessive genetic
models (corresponding to values in Table 3). The dotted line in the Composite panel depicts the calculated
CI with corresponding calculated OR for 2 alleles under an additive genetic model; of note the point estimate
(2xOR) is outside of the 95% CI for the Composite genotypic homozygous and recessive models. Diamonds
correspond to estimated OR values for these same variants in the IBD Exomes B
 rowser49; no confidence
intervals are provided.
p.L1007fs) in our adult IBD case cohort and their effect sizes using additive, genotypic, and recessive genetic
models. Under an additive model, we observed similar effect sizes for each of the 3 variants [OR = 1.43 (1.20–1.71
95%CI, P-value 4.63 × 10–5) for p.R702W; OR = 1.56 (1.18–2.06 95%CI, P-value 1.54 × 10–3) for p.G908R; and
OR = 1.84 (1.50–2.26 95%CI, P-value 1.69 × 10–9) for p.L1007fs], consistent with previously reported low to
moderate effect sizes for each allele by G
 WAS20 and data available in the IBD Exomes P
 ortal62 (Table 3, Fig. 3).
However, for the two risk alleles with homozygous cases, in the genotypic model – which estimates distinct effect
sizes for heterozygous and homozygous carriers – we observe substantially larger effects in homozygotes versus
heterozygotes for the p.R702W variant (Het OR = 1.30 [1.06–1.58 95%CI], P-value 8.77 × 1 0–3, versus Hom
OR = 4.02 [2.17–7.45 95% CI], P-value 6.86 × 1 0–6) and the p.L1007fs variant (Het OR = 1.63 [1.30–2.04 95%CI],
P-value 1.67 × 1 0–5, versus Hom OR = 10.15 [4.75–21.69 95% CI], P-value 1.38 × 1 0–12). We also calculated the
effect sizes using a recessive model for these two variants and the 22 compound heterozygotes carrying any
combination of the 3 CD risk alleles. We found that recessive effect sizes for the p.R702W and p.L1007fs variants
were similar to those observed under the homozygous genotypic model (OR = 3.91 [2.11–7.24 95% CI], P-value
2.86 × 1 0–6, and OR = 9.81 [4.59–20.94 95% CI], P-value 3.80 × 1 0–13, respectively) (Table 3, Fig. 2). Additionally,
we calculated the relative risk for the identified putative compound heterozygous (pCHET) individuals under a
recessive model. We observed that the effect size for the compound heterozygotes was also significant (OR = 4.35
[2.80–6.75 95% CI], P-value = 8.14 × 10–13), consistent with our previous observations (Table 3, Fig. 2). The calculated combined contribution of the 3 CD risk alleles under the different genetic models was as follows: additive
(OR = 1.64 [1.45–1.86 95%CI], P-value 4.58 × 10–15), genotypic (Het OR = 1.49 [1.28–1.73 95%CI], P-value 2.75
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NOD2 gene burden variant
class

Additive OR [95% CI]

Additive P-value

Recessive OR [95% CI]

Recessive P-value

Controls (ref/het/Hom)

Cases (ref/het/Hom)

pLoF only

2.69 [2.18–3.32]

5.50 × 10–20

20.74 [10.70–40.20]

2.67 × 10–19

51,501/3254/47

529/73/11

2.38 [2.01–2.82]

–24

48,253/6388/161

474/115/24

pLoF and predicted deleterious
missense

4.60 × 10

13.15 [8.50–20.37]

7.21 × 10

–31

Table 4.  Comparison of additive and recessive models for heterozygous, homozygous, and phased compound
heterozygous pLoF and predicted deleterious missense variants for NOD2 variants (MAF < 5%) for Crohn’s
Disease Risk in DiscovEHR.

× 10–7, versus Hom OR = 5.24 [3.77–7.27 95% CI], P-value 4.31 × 10–22), and recessive (OR = 4.81 [3.47–6.67 95%
CI], P-value = 1.63 × 10–25) (Table 3, Fig. 3).
Subsequently, we combined all heterozygous, homozygous, and phased compound heterozygous predicted
loss-of-function (pLoF) and predicted deleterious missense variants in NOD2 with a MAF ≤ 5% including the
3 risk alleles to calculate the CD risk using a burden test under additive and recessive models. The pLoF only
burden analysis was significant under both the additive (P-value 5.5X10–20) and recessive (P-value = 2.67 × 10–19)
models, however the risk was much higher under the recessive model (OR = 20.74 [10.70 – 40.20 95%CI] compared to the additive model (OR = 2.69 [2.18–3.32 95%CI]) (Table 4). The pLoF and predicted deleterious missense variant burden analysis showed similar results with a significantly higher risk under the recessive model:
additive (OR = 2.38 [2.01–2.82]95%CI, P-value 4.60 × 10–24) and recessive (OR = 13.15 [8.50–20.37]95%CI,
P-value 7.21 × 10–31) (Table 4). Collectively, these analyses show substantially larger effects for NOD2 homozygotes and compound heterozygotes than heterozygotes only and indicate that the genetic contribution of NOD2
alleles, in a subset of Crohn’s disease patients, is consistent with a recessive disease model.

Discussion

We use the term inflammatory bowel disease (IBD) throughout to encompass diagnoses of both Ulcerative Colitis
and Crohn’s disease in the DiscovEHR cohort, which is similar to the referral diagnosis of the pediatric patients
where some had diagnoses of ulcerative colitis, Crohn’s disease, or IBD unspecified (Table S1). Furthermore,
prior to the release of ICD-10 codes, there was no specific diagnosis code for Crohn’s disease, as it was coded as
‘regional enteritis’ (ICD-9 555), lending itself to confusion and misdiagnoses. The DiscovEHR IBD cohort is not
intended to be a ‘pure’ Crohn’s disease cohort but rather a representative sample of the adult population that is
diagnosed with IBD. Both, the pediatric and adult cohorts reflect the clinical heterogeneity of patients diagnosed
with IBD and the challenges of the clinical and molecular diagnosis of this disease.
Our observations are in line with previous analyses and meta-analyses of CD cohorts where individuals
carrying any one of the main three CD associated risk alleles (p.R702W, p.G908R, or p.L1007fs) have 2–fourfold
increased risk for developing C
 D63, whereas carriers of two or more of the same NOD2 variants have a 15–40
fold increased risk for developing C
 D33,64,65, exhibiting disease of the terminal i leum34, and earlier diagnosis (by
an average of 3 years)33. Our observations support these studies but highlight a subset of IBD cases molecularly
defined by recessive inheritance of NOD2 alleles that exhibit markedly increased risk for CD with significantly
earlier age of onset (mean age of onset among recessive NOD2 carriers in the DiscovEHR IBD cohort: 43.4y;
mean age of onset in the DiscovEHR IBD cohort: 51.5y; P-value: 4.0X10–4 by unpaired t test).
Further, while we observe a low effect size for single allele carriers, based on our allelic effect size calculations
for each of the 3 main CD risk alleles in our DiscovEHR cohort (Table 3, Fig. 3), we hypothesize that homozygous
and compound heterozygous NOD2 individuals included in large IBD GWAS cohorts have likely contributed to
a large proportion of the relative risk calculations for IBD, specifically for CD, under additive models, and that
homozygous effect sizes have been largely underappreciated or underreported. It is possible that stratification or
conditional statistical analysis of these large and heterogeneous cohorts based on NOD2 genotypes may increase
power to detect other loci that contribute to IBD.
While our observations strongly support recessive inheritance of NOD2 variants as a driver of early onset
Crohn’s disease, we observed incomplete penetrance, as evidenced by homozygous or compound heterozygous
NOD2 variant carriers that do not have a clinical presentation of I BD65–67. Penetrance and expressivity are two
major genetic concepts that play into the onset of the phenotype and the clinical presentation of monogenic
diseases68. In the case of IBD, penetrance is known to be incomplete and clinical presentation is extremely
variable. Further, the contribution of additional environmental triggers that may enhance disease onset and/
or severity in an already genetically-compromised individual should not be underestimated, especially considering that the loss of epithelial barrier function occurring during IBD allows for host exposure to up to 1014
gut microbiota69,70. Even in cases of monogenic IBD, such as IL-10 receptor d
 eficiency71–73, intestinal flora are
required for disease presentation in murine disease models74–76. Furthermore, variation in genes involved in
NOD2-dependent signaling pathways, including XIAP77–79 and TRIM2280, result in Mendelian forms of IBD. For
XIAP, and most likely TRIM22, viral triggers are required for disease onset and progression, and XIAP mutations
have variable penetrance, with only a small percentage of XIAP-deficiency patients developing CD (age of onset
between 3 months and 40 y ears64). As NOD2-deficient hosts are more susceptible to the pathogenic effects of a
changing intestinal microenvironment81, the contribution of either discrete or continuous gene-environment
exposures may further explain heterogeneity in onset and presentation of disease for genetically-sensitized
recessive NOD2 carriers.

Scientific Reports |

(2021) 11:5595 |

https://doi.org/10.1038/s41598-021-84938-8

7
Vol.:(0123456789)

www.nature.com/scientificreports/
Given the wide variability in clinical presentation of IBD, we cannot exclude the possibility that recessive
NOD2 carriers exhibit subclinical phenotypes not formally diagnosed as IBD or that they may eventually develop
IBD. It is additionally possible that recessive NOD2 carriers in the DiscovEHR cohort have a diagnosis of IBD that
has not been captured in the EHR. Detailed investigation into the medical histories of recessive NOD2 carriers
may shed light on this variable expressivity or incomplete capture of medical information. We also cannot exclude
the possibility that recessive NOD2 carriers possess additional genes or alleles that either contribute to disease
onset and severity or, alternatively, provide protection or reduced expressivity of the phenotype. Identification
of these genetic modifiers warrants future investigation both to unveil additional IBD-risk associated loci for
early onset UC and CD cases and to identify protective genes and alleles that can be used to derive therapeutic
avenues for IBD treatment and management.
In summary, in a cohort of 1,183 pediatric and early onset IBD patients, we report recessive inheritance of
rare and low frequency variants in NOD2 accounting for about 8% of probands. We assessed the contribution of
NOD2 recessive inheritance in a broader, heterogeneous cohort of adult IBD patients, similar to those recruited
for GWAS, and found that recessive inheritance of variants in NOD2 account for 6.5% of these IBD patients,
including 9.9% of CD cases. Thus, recessive inheritance of rare and low frequency NOD2 variants explain a
substantial proportion of CD cases in a pediatric cohort and a large clinical population, with significantly earlier
age of disease onset. Consistently, both pediatric and adult CD exhibit a broad spectrum of clinical presentation, suggesting a shared etiology across age groups, at least in the subgroup defined by recessive NOD2-driven
CD. Our findings indicate that deleterious NOD2 variants should be considered as strong predictors of IBD-CD
onset and implicate NOD2 as a Mendelian disease gene for early onset IBD, specifically for a molecularly defined
subset of Crohn’s disease patients.
Received: 7 October 2020; Accepted: 23 February 2021
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